glp-1/gip agonists The activity of GLP-1 and GIP for Type 2 Diabetes and Obesity Potential Use of GLP-1 and

Diab Care 42 , 507513 (2019)

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial.Lancet

When pharmacies consistently can't obtain the FDA-approved drug in quantities they need to meet patient demand, that drug is not commercially available the very definition of a shortage. Here are five questions answered about the FDA's decision to halt compounded versions of GLP-1 drugs

This content aligns with the Therapeutic Goods Administration (TGA) and Australian Health Practitioner Regulation Agency (AHPRA) guidelines as of publication

Pharmacological antagonism of the incretin system protects against diet-induced obesity

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study